Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2023-01-16 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于公司新增对外担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's new external guarantees (担保) provided to other companies, including details of the guarantee amounts, terms, and the financial status of the guaranteed companies. It includes a board opinion approving the guarantees and cumulative guarantee information. There is no indication that this is a full financial report, audit report, or earnings release. It is a regulatory announcement about financing-related guarantees, which fits best under Capital/Financing Update (CAP). The document is about financing activities (providing guarantees to facilitate financing) rather than a report or certification. The length is about 4748 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2023-01-16 Chinese
2022年第三次临时股东大会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2022 third extraordinary general meeting of shareholders of Ruikang Pharmaceutical Group Co., Ltd. It includes details about the meeting notice, attendance, voting results, and legal opinion on the meeting's validity. The document does not contain financial statements or detailed financial analysis but reports on the voting outcomes of shareholder proposals. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2162 characters, which is relatively short and focused on voting results rather than a full report or presentation.
2022-12-22 Chinese
2022年第三次临时股东大会的律师见证法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, agenda, voting procedures, and results of a specific shareholders' meeting (the 2022 third extraordinary general meeting) of a company. It details the legal compliance of the meeting process and the validity of the resolutions passed. It does not contain financial statements or financial performance data, nor is it a transcript or presentation. It is not an announcement of voting results but a legal opinion on the meeting's legality and procedures. This type of document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to official confirmation and legal opinion on shareholder voting outcomes and meeting procedures.
2022-12-22 Chinese
山东乾元律师事务所关于瑞康医药集团股份有限公司2022年员工持股计划的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 employee stock ownership plan of a listed company, 瑞康医药集团股份有限公司. It extensively discusses the legal compliance, procedures, and regulatory adherence of the employee stock ownership plan, referencing relevant laws, regulations, and regulatory guidelines. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a specific corporate action (employee stock ownership plan). It is not an announcement or brief notice but a detailed legal opinion document. This type of document fits best under the category of Regulatory Filings (RNS), as it is a compliance/legal document that does not fit into other specific categories like capital/financing update or board/management changes. The document length (over 11,000 characters) and detailed content confirm it is not a mere announcement or certification but a substantive legal opinion report.
2022-12-19 Chinese
瑞康医药独立董事对第四届董事会第二十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a specific board meeting (the 25th meeting of the 4th board) and related matters, specifically about a related-party transaction involving share transfer. It references compliance with company articles, laws, and governance rules, and includes signatures of independent directors. The content is focused on board/management information and governance-related approval rather than financial results or report publication. The document length is short (724 characters) and it is not a report or announcement of a report publication. Therefore, it fits best under Board/Management Information (MANG).
2022-12-15 Chinese
第四届监事会第二十三次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at the 23rd meeting of the 4th Supervisory Board of Ruikang Pharmaceutical Group Co., Ltd. It details the approval of a related-party transaction involving the acquisition of shares in a subsidiary company. The document includes voting results and confirms compliance with relevant laws and company regulations. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is an official announcement of a board/management decision related to a corporate transaction and governance. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1100 characters), and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2022-12-15 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.